SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-24-002085
Filing Date
2024-01-08
Accepted
2024-01-08 08:30:13
Documents
14
Period of Report
2024-01-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm242328d1_8k.htm   iXBRL 8-K 26395
2 EXHIBIT 99.1 tm242328d1_ex99-1.htm EX-99.1 56807
6 GRAPHIC tm242328d1_ex99-1img001.jpg GRAPHIC 3819
  Complete submission text file 0001104659-24-002085.txt   275729

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rigl-20240108.xsd EX-101.SCH 3006
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rigl-20240108_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rigl-20240108_pre.xml EX-101.PRE 22353
8 EXTRACTED XBRL INSTANCE DOCUMENT tm242328d1_8k_htm.xml XML 3331
Mailing Address 611 GATEWAY BOULEVARD, SUITE 900 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BOULEVARD, SUITE 900 SOUTH SAN FRANCISCO CA 94080 650-624-1100
RIGEL PHARMACEUTICALS INC (Filer) CIK: 0001034842 (see all company filings)

IRS No.: 943248524 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-29889 | Film No.: 24518486
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)